The recent halving of prices for GLP-1 obesity treatments in the U.S. is drawing attention for its potential ripple effects on the South Korean market. Novo Nordisk’s decision to slash the cost of its obesity drug Wegovy by up to 50% in the U.S. has sparked speculation about possible pricing pressures in South Korea.
Industry sources reported on Tuesday that Novo plans to adjust the wholesale acquisition cost (WAC) of GLP-1 treatments to 675 USD per month starting January 1 next year. This represents a 50% reduction from Wegovy’s current price.
The price cuts will also apply to Ozempic, a Type 2 diabetes medication, and Rybelsus, an oral diabetes treatment. Both will see their prices reduced from about 1,000 USD to the same 675 USD level, regardless of dosage or administration method.
Analysts view this price reduction as more than just a marketing ploy, but rather a strategic move. They cite disappointing clinical results for Novo’s next-generation obesity drug candidate, CagriSema, and the looming patent expiration for semaglutide, Wegovy’s active ingredient, in several countries as key factors.
Eli Lilly, already a significant player in the U.S. market, has hinted at plans to offer obesity medications priced comparably to a cup of coffee. This shift suggests the market is moving from data-driven competition to a phase of aggressive price warfare.
However, experts predict the immediate impact on the South Korean market may be limited. The pricing and distribution structures in South Korea differ significantly from those in the U.S., meaning changes in overseas prices don’t necessarily translate to lower domestic prices.
In South Korea, obesity medications are currently not covered by national health insurance. The most feasible path to lower prices would be inclusion in the reimbursement system. Yet, industry insiders believe this is unlikely in the short term due to concerns about the financial burden on the healthcare system.
Demand dynamics also play a crucial role. Even at current price points, prescription demand outstrips supply. With robust demand at existing prices, manufacturers have little incentive to voluntarily reduce costs.
Nevertheless, some speculate that if Wegovy implements price reductions ahead of its patent expiration in South Korea, or if domestic pharmaceutical companies like Hanmi begin launching their own obesity drugs, it could trigger price competition in the local market.
An industry insider noted that Korean consumers are typically very price-sensitive. If Wegovy lowers its prices in South Korea and it sees a significant shift in patient preferences, competing companies may well consider adjusting their pricing strategies.